Clinical evolution of acute bronchitis in Colombian children between 2 and 14 years treated with Hedera helix EA575 syrup

Aim: To describe the experience of use and clinical evolution of patients with acute bronchitis treated with Hedera helix EA575 syrup for seven days. Methods: A descriptive observational study based on clinical records, which included patients between 2–14 years old with acute bronchitis prescribed by their doctor Hedera helix EA575 syrup. Sociodemographic data and the time of evolution of the cough were taken from the baseline consultation. Treatment-related variables, BSS-Pediatric Scale, visual analogue cough scale, and verbal descriptive cough score were taken from the follow-up. The satisfaction with the treatment and its success were evaluated after 14 days. Results: 80 patients between 2 and 12 years old were included. The median number of cough days was eight days. After 7 and 14 days of treatment, 50% and 76% had resolved the cough, respectively. On day 14, coughing was frequent without interfering with activities in 1 patient. The BSS-pediatric score decreased at each follow-up. Median day-and-night cough VAS was zero for day 14. Awakenings due to coughing decreased from 3 at baseline to 0 per week. 98.75% of the patients were satisfied with the treatment, and none presented adverse events. Conclusions: After seven days of treatment, half of the patients had resolved cough and night awakenings; it is suggested that treatment with Hedera helix EA575 could be beneficial and of low risk.